newsfilter
← Latest News
GlobeNewswire·

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patientsEstablished a research collaboration with Novo Nordisk to develop an epigenomic